Clinical economics review: Cost-effectiveness of treatment alternatives for gastro-oesophageal reflux disease

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 6, 1996, Pages 865-873

  Sridhar, S ^a   Huang, J ^a   O'brien, B J ^b   Hunt, R H ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b CENTRE FOR EVALUATION OF MEDICINES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CIMETIDINE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMICS; GASTROESOPHAGEAL REFLUX; HUMAN; PRIORITY JOURNAL; RECURRENT DISEASE;

EID: 0029821009     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1996.72241000.x     Document Type: Article

References (49)

1. Wienbeck M, Barnert J. Epidemiology of reflux disease and reflux oesophagitis. Scand J Gastroenterol 1989; 24 (Suppl. 156): 7-13.
2. Nebel OT, Fornes MF, Castell DO. Symptomatic gastrooesophageal reflux: incidence and precipitating factors. Am I Dig Dis 1976; 21: 953-6.
3. Richter J, Castel DO. Gastroesophageal reflux: pathogenesis, diagnosis and therapy. Ann Intern Med 1982; 97: 93-103.
4. Heading RC. Epidemiology of oesophageal reflux disease. Scand J Gastroenterology 1989; 24 (Suppl. 168): 33-7.
5. Gallup Organization National Survey. Heartburn across America. Princetown. New Jersey: Gallup Organization Inc., 1988.
6. Chiba N, Wilkinson J, Hunt RH. Symptom relief in erosive GERD: a meta-analysis. Am J Gastroenterol 1993; 88: A1486.
7. Chiba N, de Gara CJ, Burget DW, Wilkinson J, Hunt RH. Rapidity of healing in GERD: a comparison of different drug classes by meta-analysis. Gastroenterology 1993; 104: A53.
8. Commonwealth of Australia: Guideline for the Pharmaceutical industry on preparation of submissisions to the Pharmaceutical Benefits Advisory Committee: Including submissions involving economic analysis. Woden (ACT): Department of Health, Housing and Community Services. 1990.
9. Detsky A. Guidelines for preparation of economic analysis of pharmaceutical products: a draft document for Ontario and Canada. Pharmacoeconomics 1993; 321: 354-61.
10. Leaf A. Cost-effectiveness as a criterion for Medicare coverage. N Engl J Med 1989; 321: 898.
11. Harvey RF, Gordon PC, Hadley N, et al. Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis. Lancet 1987; ii: 1200-3.
12. De Caestecker JS, Blackwell JN, Pryde A, Heading RC. Daytime gastro-oesophageal reflux is important in oesophagitis. Gut 1987; 28: 519-26.
13. Hamilton JW, Boisen RJ, Yamamoto DT, Wagner JL, Reichelderfer M. Sleeping on a wedge diminishes exposure of the esophagus to refluxed acid. Dig Dis Sci 1988; 33: 518-22.
14. Schindlbeck NE, Heinrich C, Dendorfer A, Pace F, Muller-Lissner SA. Influence of smoking and esophageal intubation on esophageal pHmetry. Gastroenterology 1987; 92: 1994-7.
15. Vitale GC, Cheadle WG, Patel B, et al. The effect of alcohol on nocturnal gastroesophageal reflux. J Am Med Assoc 1987; 258: 2077-9.
16. Higgs RH. Smyth RD, Castell DO. Gastric alkalinization: Effect on lower esophageal-sphincter pressure and serum gastrin. N Engl J Med 1974; 291: 486-90.
17. Graham DY, Patterson DJ. Double-blind comparison of liquid antacid and place in the treatment of symptomatic reflux esophagitis. Dig Dis Sci 1983; 28: 559-63.
18. Ceccatelli P, Janssens J, Vantrappen G, Cucchiara S. Cisapride restores the decreased lower oesophageal sphincter pressure in reflux patients. Gut 1988; 29: 631-5.
19. Smout AJPM, Bogaard JW, Grade AC, et al. Effects of cisapride, a new gastrointestinal prokinetic substance, on interdigestive and postprandial motor activity of the distal oesophagus in man. Gut 1985; 26: 246-51.
20. Galmiche JP, Brandstatter G, Evreux M, et al. Combine therapy with cisapride and cimetidine in severe reflux oesophagitis: a double blind controlled trial. Gut 1988; 29: 675-81.
21. Richter JE, Long JF. Cisapride for gastroesophageal reflux disease: a placebo-controlled, double-blind study. Am J Gastroenterol 1995; 90: 423-30.
22. Tytgat GN, Anker Hansen OJ, Carling L, et al. Effect of cisapride on relapse of reflux oesophagitis. healed with antisecretory drugs. Scand J Gastroenterol 1992; 27: 175-83.
23. Tytgat GNJ, Blum AL, Verlinden M. Prognostic factors for relapse and maintenance treatment with cisapride in gastrooesophageal reflux disease. Aliment Pharmacol Ther 1995; 9: 271-80.
24. 2RA (famotidine). Am J Ther 1995; 2: 304-13.
25. Bell NJV, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastrooesophageal reflux disease. Digestion 1992; 51 (Suppl. 1): 59-67.
26. Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9 (Suppl. 1): 3-7.
27. Bell NJV, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992; 33: 118-24.
28. Roufail W, Belsito A, Robinson M, Barish C, Rubin A. Glaxo erosive esophagitis study group. Ranitidine for erosive oesophagitis: a double-blind, placebo-controlled study. Aliment Pharmacol Ther 1992; 6: 597-607.
29. Johnson NJ, Boyd EJS, Mills JG, Wood JR. Acute treatment of reflux oesophagitis: a multicentre trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s. Aliment Pharmacol Ther 1989; 3: 259-66.
30. Cloud ML, Offen WW, Robinson M. Nizatidine versus placebo in gastroesophageal reflux disease: a 12-week, multicenter, randomized, double-blind study. Am J Gastroenterol 1991; 86: 1735-42.
31. Quik RFP, Cooper MJ, Gleeson M, et al. A comparison of two doses of nizatidine versus placebo in the treatment of reflux oesophagitis. Aliment Pharmacol Ther 1990; 4: 201-11.
32. Bate CM, Keeling PWN, O'Morain SP, et al. Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations. Gut 1990; 31: 968-72.
33. Vantrappen G, Rutgeerts L, Schurmans P, Coenegrachts JL. Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis. Dig Dis Sci 1988; 33: 523-9.
34. Robinson M, Decktor DL, Maton PN, et al. Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis. Aliment Pharmacol Ther 1993; 7: 67-73.
35. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 1987.
36. Bate, CM. Cost-effectiveness of omeprazole in the treatment of reflux oesophagitis. Br J Med Econ 1991; 1: 53-61.
37. Bate CM, Richardson PDL. A one year model for the cost-effectiveness of treating reflux oesophagitis. Br J Med Econ 1992; 2: 5-11.
38. Hillman AL, Bloom B, Fendrick AM, et al. Cost and quality effects of alternative treatments for persistent gastroesophageal reflux disease. Arch Intern Med 1992; 152: 1467-72.
39. Jonsson B, Stalhammer NO. The cost-effectiveness of omeprazole in intermittent and maintenance treatment of reflux oesophagitis - the case of Sweden. Br J Med Econ 1993; 6: 111-26.
40. Lindberg G. Omeprazole vs ranitidine in reflux oesophagitis. Pharmacoeconomics 1994; 5 (Suppl. 3): 27-34.
41. Bloom B. Cost and quality effects of treating erosive esophagitis: a re-evaluation. Pharmacoeconomics 1995; 8: 139-46.
42. Bate CM. Omeprazole vs ranitidine and cimetidine in reflux oesophagitis: the British perspective. Pharmacoeconomics 1994; 5 (Suppl. 3): 35-43.
43. Hillman AL. Economic analysis of alternative treatments for persistent gastro-oesophageal reflux disease. Scand J Gastroenterol 1994; 29 (Suppl. 201): 8-102.
44. Stalhammer NO. Assessing the cost-effectiveness of medical treatments in acid-related diseases. Scand J Gastroenterol 1993; 28 (Suppl. 199): 8-13.
45. Harris RA, Nease RF. Economic heartburn: average cost-effectiveness and gastroesophageal reflux disease. Gastroenterology 1995; 108: 303-4.
46. Freston JW, Malagelada JR, Petersen H, McCloy RF. Critical issues in the management of gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 1995; 7: 577-86.
47. Jones RH, Basanquet N, Johnson NJ, Chong SL. Cost-effective management strategies for acid-peptic disorders. Br J Med Econ 1994; 7: 99-114.
48. Hatlebakk JG, Berstad A, Carling L, et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis: Results of a Scandinavian multicentre trial. Scand J Gastroenterol 1993; 28: 224-8.
49. O'Brien B, Goeree R, Mohamed AH, Hunt R. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada. Arch Intern Med 1995; 155: 1958-64.